SCHEDULE: Forbion Growth Discloses 7.1% Stake in MapLight Therapeutics

Forbion Growth Opportunities Fund III Cooperatief U.A. and Forbion Growth III Management B.V. have disclosed a 7.1% beneficial ownership stake in MapLight Therapeutics, Inc.

Summary

• Forbion Growth Opportunities Fund III Cooperatief U.A. and Forbion Growth III Management B.V. (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The Reporting Persons beneficially own 3,226,400 shares of MapLight Therapeutics, Inc.'s Voting Common Stock.
• This ownership represents approximately 7.1% of the outstanding Common Stock.
• The percentage is based on 45,373,033 shares of Common Stock outstanding as of November 24, 2025, as reported by MapLight Therapeutics in its Form 10-Q filed on December 4, 2025.
• Forbion Growth III COOP directly owns the shares, and Forbion Growth III, as its director, may be deemed to have shared voting and investment power.
• Both Reporting Persons are organized under the laws of the Netherlands.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a growth-focused institutional investor typically signals confidence in the company's long-term value and potential.

Positives

• A significant institutional investor, Forbion Growth, has disclosed a substantial 7.1% stake in MapLight Therapeutics, indicating confidence in the company's future prospects.
• The investment by a growth opportunities fund suggests a belief in the company's long-term potential and strategic direction.

Future Outlook

This filing does not contain forward-looking statements or guidance from MapLight Therapeutics, Inc. It solely reports a change in beneficial ownership by an external investment entity.

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by a specialized growth fund like Forbion Growth in a biotechnology company like MapLight Therapeutics often signals a positive outlook on the company's pipeline, market potential, or strategic direction within the competitive biotech landscape. Such investments can attract further investor interest and validate the company's business model.

Stakeholder Impact

• Shareholders may view the entry of a significant institutional investor as a positive signal, potentially increasing confidence in the company's stock.
• The company's management might benefit from the strategic insights and long-term perspective that a large institutional shareholder like Forbion Growth can bring.

Key Dates

Recommendation

A seasoned investor would likely view Forbion Growth's 7.1% stake as a strong vote of confidence in MapLight Therapeutics. Forbion Growth is a specialized growth fund, and their significant investment suggests they see substantial upside potential in the company. This institutional backing could attract further investor interest and potentially lead to a re-evaluation of the stock's intrinsic value, making it a 'buy' recommendation for investors looking for growth opportunities.

Keywords

MapLight Therapeutics, Forbion Growth, Institutional Ownership, Beneficial Ownership, Voting Common Stock, SEC Filing, Schedule 13G, Biotechnology Investment, Growth Fund